Modern Rheumatology · 2012 · 11 citations · 10 references
MedicineInternal MedicinePharmacotherapyDermatopathologyImmunotherapyRheumatologyInflammatory Skin DiseasesSystemic SclerosisAdverse Treatment EffectsJoint Mobility PreservationJoint Mobility TestingMedication Adverse EffectsMusculoskeletal InvolvementPulmonary Hypertension In SclerodermaScleroderma TreatmentSystemic Sclerosis Skin Involvement
In this pilot study, the effect of low-dose imatinib mesylate (100 mg/day) on cutaneous involvement in patients with systemic sclerosis (SSc) was analyzed. Three patients with SSc were treated with 100 mg/day of imatinib mesylate for 6 months because of pulmonary arterial hypertension refractory to conventional treatments, including beraprost, bosentan, sildenafil, and epoprostenol. Changes in cutaneous involvement were evaluated at 1, 3, and 6 months. During the treatment, the total skin score gradually improved in all of the patients. Contracture of phalanges was attenuated in two patients, one of whom also experienced the partial restoration of large-joint mobility. Nailfold bleeding, initially seen in two patients, was gradually attenuated and had completely disappeared at 6 months. In all patients, Raynaud’s phenomenon was attenuated at around 3 months and had completely disappeared at 6 months. Although transient renal dysfunction was observed in one patient, none of the patients experienced common adverse effects of imatinib, such as edema, nausea, rash, and musculoskeletal pain. These clinical data indicate the tolerability and efficacy of low-dose imatinib in SSc, especially against cutaneous vascular involvement, including Raynaud’s phenomenon and nailfold bleeding.
10
Imatinib for refractory chronic graft-versus-host disease with fibrotic features
Attilio Olivieri, Franco Locatelli, Marco Zecca et al. · Blood · 2009 · 233 citations
Endothelial Fli1 Deficiency Impairs Vascular Homeostasis
Yoshihide Asano, Lukasz Stawski, Faye N. Hant et al. · American Journal Of Pathology · 2010 · 194 citations · Full text
Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?
Jo Nadine Fleming, Richard A. Nash, D. O. McLeod et al. · PLoS ONE · 2008 · 184 citations · Full text
Medicine, Dermatology, Pathology +15